Advertisement
KLRS vs PTHS
Which Stock Would AI Choose? Kalaris Therapeutics (KLRS) vs. Pelthos Therapeutics (PTHS) Stock Comparison
Key Takeaways
- Kalaris Therapeutics (KLRS) is a clinical-stage, pre-revenue biopharmaceutical company, while Pelthos Therapeutics (PTHS) is a commercial-stage company with multiple marketed products.
- Both names trade well below their 52-week highs, reflecting a risk-off tone across smaller-cap healthcare equities in recent months.
- KLRS reported roughly $93.5 million in cash as of mid-2026, funding its lead retinal disease program; PTHS generates revenue and carries a "Strong Buy" analyst consensus.
- Tickeron AI Verdict: PTHS edges out KLRS on the strength of its commercial-stage revenue base and more diversified market positioning.
- For deeper context, explore KLRS Major News and KLRS Today's Price Move, as well as PTHS Major News and PTHS Today's Price Move.
- To see how automated strategies are positioning across the market, explore the curated Trending AI Robots.
Introduction
Investors weighing exposure to healthcare equities often face a choice between companies at very different stages of maturity. This stock comparison examines KLRS, a clinical-stage developer of retinal disease treatments, and PTHS, a commercial-stage specialty biopharmaceutical company. The two names appeal to different profiles: KLRS suits investors comfortable with binary clinical-development risk and a long catalyst timeline, while PTHS attracts those seeking a revenue-generating business with an existing product portfolio. Understanding their relative performance and market positioning helps clarify which profile aligns with current conditions.
KLRS Overview and Recent Performance
Kalaris Therapeutics, Inc. (KLRS) is a clinical-stage biopharmaceutical company developing treatments for prevalent retinal diseases. Its lead candidate, TH103, is an anti-VEGF (vascular endothelial growth factor) therapy engineered for extended intraocular retention, currently being evaluated for neovascular age-related macular degeneration (nAMD, a leading cause of vision loss).
The company remains pre-revenue, with patient dosing ongoing in a Phase 1b/2 study. Preliminary data is anticipated in the first half of 2027, and management has indicated Phase 3 trials could initiate around year-end 2027. As of mid-2026, KLRS reported approximately $93.5 million in cash, cash equivalents, and marketable securities, which it expects to fund operations into its next milestones.
Recent market activity has been volatile. The stock has declined substantially from its 52-week high, and its market capitalization has compressed in recent weeks. Sentiment has been shaped by a mix of supportive sell-side initiations and a notable independent ratings downgrade, as well as an increased institutional stake disclosed in late 2026. Broader small-cap biotech risk appetite remains a key driver of the share price.
PTHS Overview and Recent Performance
Pelthos Therapeutics Inc. (PTHS) is a commercial-stage biopharmaceutical company with several marketed products, including ZELSUVMI for molluscum contagiosum (a viral skin infection), XEPI cream for impetigo (a bacterial skin infection), and XEGLYZE for head lice. This diversified, revenue-generating portfolio distinguishes it from earlier-stage peers.
Despite its commercial footing, PTHS has experienced a significant drawdown from its 52-week high, and its market capitalization has contracted sharply in recent months. The stock carries a notably high beta, indicating above-average volatility relative to the broader market. Analysts, however, maintain a "Strong Buy" consensus with an average price target well above recent trading levels, reflecting expectations for revenue growth from its product lineup.
Recent sentiment has been shaped by new analyst coverage with Overweight ratings and growing institutional participation, even as the share price remains under pressure. The company's relatively small share count and limited trading liquidity can amplify price swings.
Trending AI Robots
For traders who prefer a systematic approach, Tickeron's Trending AI Robots page offers a curated view of its AI trading bots. Tickeron maintains hundreds of AI Trading Bots that trade thousands of different tickers, each with its own trading style, strategy, timeframe, performance record, statistics, and basket of underlying symbols. Rather than listing every available bot, the Trending AI Robots section surfaces only those considered most suitable for current market conditions. This filtering helps users focus on strategies demonstrating relevance to prevailing trends. Explore the Trending AI Robots page to see which automated approaches are currently in focus.
Head-to-Head Comparison
The clearest contrast between these two stocks is stage of development. PTHS is already selling products and projecting meaningful revenue growth, while KLRS has no product revenue and depends on clinical success and continued financing. This difference drives their risk profiles: KLRS carries concentrated, binary risk around a single lead asset, whereas PTHS spreads risk across multiple marketed products.
Growth drivers also diverge. For KLRS, the catalysts are clinical readouts and regulatory milestones, which can produce large, step-function moves in either direction. For PTHS, growth is tied to commercial execution and expanding uptake of its existing therapies. In terms of market sentiment, PTHS enjoys a stronger consensus rating, while KLRS commands a higher implied upside relative to its current price, reflecting its earlier stage and higher discount.
Tickeron AI Verdict
Based on observable factors such as revenue generation, market positioning, and the concentration of risk, Tickeron's AI would likely favor PTHS in the current environment. A commercial-stage company with an active product portfolio generally offers more stable and diversified fundamentals than a pre-revenue, single-asset developer, even when both stocks are trading below their highs. That said, KLRS retains substantial catalyst optionality tied to upcoming clinical milestones, which could shift relative positioning quickly. The verdict reflects a probabilistic read of stability and near-term positioning rather than a definitive forecast, and conditions can change as new data and results emerge.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is KLRS is a Hold and PTHS is a Hold.
KLRS's Stochastic Oscillator descends into oversold zone
The Stochastic Oscillator for KLRS moved into oversold territory on November 11, 2026. Be on the watch for the price uptrend or consolidation in the future. At that time, consider buying the stock or exploring call options.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where KLRS's RSI Indicator exited the oversold zone, 33 of 41 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 80%.
The Moving Average Convergence Divergence (MACD) for KLRS just turned positive on October 28, 2026. Looking at past instances where KLRS's MACD turned positive, the stock continued to rise in 39 of 47 cases over the following month. The odds of a continued upward trend are 83%.
Following a +19.80% 3-day Advance, the price is estimated to grow further. Considering data from situations where KLRS advanced for three days, in 197 of 232 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 11, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on KLRS as a result. In 90 of 98 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where KLRS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
KLRS broke above its upper Bollinger Band on November 05, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for KLRS entered a downward trend on November 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 12 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 41 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.999) is normal, around the industry mean (3.498). P/E Ratio (-1.277) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 88 (best 1 - 100 worst), indicating slightly worse than average price growth. KLRS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. KLRS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
PTHS's RSI Oscillator remains in oversold zone for 6 days
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a +0.75% 3-day Advance, the price is estimated to grow further. Considering data from situations where PTHS advanced for three days, in 107 of 135 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
PTHS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for PTHS turned negative on October 23, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 26 similar instances when the indicator turned negative. In 25 of the 26 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PTHS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for PTHS entered a downward trend on November 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 6 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-23.874) is normal, around the industry mean (3.498). P/E Ratio (-0.327) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (1.470) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 7 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 95 (best 1 - 100 worst), indicating slightly worse than average price growth. PTHS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PTHS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
KLRS | ||
|---|---|---|
OUTLOOK RATING 1..100 | 8 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 41 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | |
SMR RATING 1..100 | 98 | |
PRICE GROWTH RATING 1..100 | 88 | |
P/E GROWTH RATING 1..100 | 12 | |
SEASONALITY SCORE 1..100 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| KLRS | PTHS | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 80% | 1 day ago 90% |
| Stochastic ODDS (%) | 1 day ago 89% | N/A |
| Momentum ODDS (%) | 1 day ago 90% | N/A |
| MACD ODDS (%) | 1 day ago 83% | 1 day ago 90% |
| TrendWeek ODDS (%) | 1 day ago 90% | 1 day ago 90% |
| TrendMonth ODDS (%) | 1 day ago 90% | 1 day ago 90% |
| Advances ODDS (%) | 6 days ago 85% | 3 days ago 79% |
| Declines ODDS (%) | 2 days ago 90% | 7 days ago 90% |
| BollingerBands ODDS (%) | 1 day ago 90% | 1 day ago 90% |
| Aroon ODDS (%) | 1 day ago 90% | 1 day ago 87% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
KLRS’s FA Score shows that 1 FA rating(s) are green while PTHS’s FA Score has 2 green FA rating(s).
- KLRS’s FA Score: 1 green, 4 red.
- PTHS’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
KLRS’s TA Score shows that 4 TA indicator(s) are bullish while PTHS’s TA Score has 3 bullish TA indicator(s).
- KLRS’s TA Score: 4 bullish, 4 bearish.
- PTHS’s TA Score: 3 bullish, 3 bearish.
Price Growth
KLRS (@Biotechnology) experienced а -5.94% price change this week, while PTHS (@Biotechnology) price change was -7.49% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -0.49%. For the same industry, the average monthly price growth was -6.84%, and the average quarterly price growth was -13.86%.
Reported Earning Dates
KLRS is expected to report earnings on Mar 23, 2027.
PTHS is expected to report earnings on Nov 12, 2026.
Industries' Descriptions
@Biotechnology (-0.49% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
KLRS and
Correlation & Price change
A.I.dvisor indicates that over the last year, KLRS has been loosely correlated with PTHS. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if KLRS jumps, then PTHS could also see price increases.
| Ticker / NAME | Correlation To KLRS | 1D Price Change % | ||
|---|---|---|---|---|
| KLRS | 100% | +1.60% | ||
| PTHS - KLRS | 43% Loosely correlated | +5.51% | ||
| CGEN - KLRS | 29% Poorly correlated | N/A | ||
| CAMP - KLRS | 28% Poorly correlated | -3.00% | ||
| MESO - KLRS | 27% Poorly correlated | -2.43% | ||
| RCKT - KLRS | 26% Poorly correlated | +1.22% | ||
More | ||||
PTHS and
Correlation & Price change
A.I.dvisor indicates that over the last year, PTHS has been loosely correlated with ABOS. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if PTHS jumps, then ABOS could also see price increases.
| Ticker / NAME | Correlation To PTHS | 1D Price Change % | ||
|---|---|---|---|---|
| PTHS | 100% | +5.51% | ||
| ABOS - PTHS | 55% Loosely correlated | N/A | ||
| PMN - PTHS | 42% Loosely correlated | -5.53% | ||
| GYRE - PTHS | 41% Loosely correlated | +0.71% | ||
| DRUG - PTHS | 38% Loosely correlated | +3.72% | ||
| PASG - PTHS | 38% Loosely correlated | +5.82% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| SEA | 20.06 | 0.43 | +2.19% |
| U.S. Global Sea to Sky Cargo ETF (SEA) | |||
| FDCF | 50.83 | 0.48 | +0.96% |
| Fidelity Disruptive Communications ETF (FDCF) | |||
| XLFX | 30.60 | N/A | N/A |
| Corgi U.S. Financials 2x Daily ETF (XLFX) | |||
| HFSI | 33.89 | -0.02 | -0.06% |
| Hartford Strategic Income ETF (HFSI) | |||
| RSPD | 58.06 | -0.18 | -0.31% |
| Invesco S&P 500 Equal Weight Consumer Discretionary ETF (RSPD) | |||